Characterization of Gαs and Gαolf activation by catechol and non-catechol dopamine D1 receptor agonists
- PMID: 40384932
- PMCID: PMC12084000
- DOI: 10.1016/j.isci.2025.112345
Characterization of Gαs and Gαolf activation by catechol and non-catechol dopamine D1 receptor agonists
Abstract
The dopamine D1 receptor (D1R) couples to Gαs and Gαolf and is crucial in regulating neurological and neuropsychiatric functions. In the brain, Gαolf is predominantly found in the striatum whereas Gαs is expressed elsewhere. Our in vitro assays revealed that the tetracyclic catechol agonists dihydrexidine, methyl-dihydrexidine, doxanthrine, and the non-catechol compounds PF-8294, PF-6142 exerted full agonism for Gαs coupling but only partial agonism for Gαolf coupling. In contrast, the non-catechol agonist tavapadon acted as a full agonist at Gαolf and a partial agonist at Gαs. The effects of these ligands on the thalamocortical and striatonigral electrophysiological events, as well as on the locomotor activity and cognitive function of mice agreed with their selectivity profiles in vitro. These findings suggest the possibility of achieving region-specific pharmacology and open new directions for developing D1R drugs to treat relevant neurological and neuropsychiatric disorders.
Keywords: Molecular biology; Neuroscience.
© 2025 The Author(s).
Conflict of interest statement
The authors declare no competing financial interests.
Figures








Similar articles
-
The Signaling and Pharmacology of the Dopamine D1 Receptor.Front Cell Neurosci. 2022 Jan 17;15:806618. doi: 10.3389/fncel.2021.806618. eCollection 2021. Front Cell Neurosci. 2022. PMID: 35110997 Free PMC article.
-
Gs- versus Golf-dependent functional selectivity mediated by the dopamine D1 receptor.Nat Commun. 2018 Feb 5;9(1):486. doi: 10.1038/s41467-017-02606-w. Nat Commun. 2018. PMID: 29402888 Free PMC article.
-
Quantitative changes in Galphaolf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants.Neuropsychopharmacology. 2007 May;32(5):1109-21. doi: 10.1038/sj.npp.1301230. Epub 2006 Oct 25. Neuropsychopharmacology. 2007. PMID: 17063155
-
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation.Front Pharmacol. 2020 Jul 7;11:1005. doi: 10.3389/fphar.2020.01005. eCollection 2020. Front Pharmacol. 2020. PMID: 32733245 Free PMC article.
-
Dihydrexidine--the first full dopamine D1 receptor agonist.CNS Drug Rev. 2004 Fall;10(3):230-42. doi: 10.1111/j.1527-3458.2004.tb00024.x. CNS Drug Rev. 2004. PMID: 15492773 Free PMC article. Review.
Cited by
-
Estimation of Dopamine D1 Receptor Agonist Binding Kinetics Using Time-Resolved Functional Assays: Relation to Agonist-Induced Receptor Internalization by Investigational Antiparkinsonian Therapeutics.ACS Chem Neurosci. 2025 Jul 2;16(13):2502-2512. doi: 10.1021/acschemneuro.5c00270. Epub 2025 Jun 19. ACS Chem Neurosci. 2025. PMID: 40537032 Free PMC article.
References
-
- Waszczak B.L., Martin L.P., Finlay H.E., Zahr N., Stellar J.R. Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia. J. Pharmacol. Exp. Ther. 2002;300:850–861. doi: 10.1124/jpet.300.3.850. - DOI - PubMed
-
- Vermeulen R.J., Drukarch B., Sahadat M.C., Goosen C., Wolters E.C., Stoof J.C. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov. Disord. 1994;9:664–672. doi: 10.1002/mds.870090613. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Molecular Biology Databases